Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Omega Therapeutics Publishes Epigenomic Controller OTX-2002 Preclinical Data In Nature Communications

Author: Benzinga Newsdesk | September 17, 2024 07:13am

Treatment with OTX-2002 led to controlled downregulation of MYC gene expression and resulted in significant inhibition of tumor growth as a monotherapy and in combination with standard of care agents in preclinical models of HCC
Proof-of-concept data for OTX-2002 support potential of epigenomic controllers to effectively target and modulate expression of nearly any human gene, including historically undruggable targets
Data further validate the OMEGA platform's potential to rapidly and prospectively design, develop and advance programmable epigenomic mRNA medicines for the treatment of a broad range of diseases

Posted In: OMGA